High levels of prostaglandins are produced in human oropharyngeal carcinoma (OPC). Five human OPC cell lines tested expressed both isoforms of cyclooxygenases (COX). The pan-COX inhibitor ketorolac continuously and significantly decreased PGE 2 production and IL-6 and IL-8 levels in all OPC cell lines tested, but did not affect IL-1␣, GM-CSF levels, or in vitro tumor cell growth. In contrast, ketorolac reduced OPC growth in vivo. The OPC cell lines used express the IL-6 receptor, and IL-6 stimulation of these cells causes transduction to occur via STAT3 pathway activation. Coincubation with OPC cell lines with conditioned medium from a TPA-exposed HL-60 cells stimulated growth proportional to the IL-6 levels measured in the conditioned medium. This growth effect was specifically inhibited by anti-IL-6 antibody.
Oropharyngeal cancer (OPC) arises within an environment in which there may be chronic exposure to a range of inflammatory stimuli, including bacterial endotoxins as well as chemical carcinogens such as tobacco combustion products (1) . OPCs have been reported to produce a variety of eicosanoids that may affect cancer cell proliferation (2, 3) , inflammatory cell proliferation (4), or inhibit the immune response (5) . The prostaglandins are produced by the catalytic action of two isoforms of prostaglandin endoperoxide synthase or cyclooxygenase (COX), specifically COX-1 and COX-2, on arachidonic acid (AA) (6, 7) . COX-1 is thought to be expressed constitutively. In contrast, expression of COX-2 is induced in response to a variety of physiological stimuli including cytokines, growth factors, bacterial endotoxins, phorbol esters, chemical carcinogens, and inflammatory mediators (8 -10) . Increased amounts of COX-2 mRNA and protein have been observed in human tumors of several lineages (11) (12) (13) (14) , particularly colon cancer (15) . Inhibitors of COX-2 can modulate apoptosis and suppress carcinogenesis, and suggest that this is the basis for the favorable effect of aspirin and nonsteroidal antiinflammatory drugs on reducing colon cancer frequency (16) . Studies have suggested that the effects of COX-2 are mediated through the regulation of cytokine production (17, 18) , but controversy exists as to the precise role of COX activity in the progression of cancer (19) . Highly selective COX-2 inhibitors have been developed to avoid the occurrence of gastrointestinal bleeding associated with systemic administration of pan-COX inhibitors. To minimize systemic exposure and maximize delivery to the site of action, the concept of using an NSAID-containing oral rinse was developed to treat periodontitis, a chronic infectious inflammatory disease of the oral cavity (20) . Ketorolac tromethamine, a pan-COX inhibitor, was developed for this application due to its demonstrated potency in the nanomolar range as well as lack of irritation (21, 22) . A tailored formu-lation of the drug allowed for desirable gingival penetration resulting in favorable tissue residence time (23) . Local administration of ketorolac reduces the risk of gastric toxicity associated with other systemically administered pan-COX inhibitor. In these periodontal trials, ketorolac was effective in completely inhibiting pan-COX activity without any significant subjective side effect. Consequently, in this setting there is no incentive for narrowing the spectrum of the COX enzyme inhibition. Furthermore, emerging data suggest that COX-1 activity may contribute to carcinogenesis, so that maintaining pan-COX inhibition may be beneficial (24 -26) .
An important question is, How general is the contribution of COX biology to the development of other epithelial cancers? Can the frequency of other cancers be reduced comparably to what is seen for colon cancer? To address this question, we have evaluated the potential contribution of COX activity to the development of OPC. Up-regulation of the COX-2 isoenzyme in head and neck cancers has been reported recently (11) . This paper explores a series of issues related to the potential mechanism of COX Јs role in OPC. Our hypothesis in these studies is that COX activity is having a comparable role in OPC to the mechanism of action suggested by Potter for COX activity in the development of B cell plasmacytomagenesis (27) . The essential elements of Potter's model include prostaglandin E 2 (PGE 2 ) -dependent recruitment of inflammatory cells, production and local release of interleukin 6 (IL-6), as well as IL-6-dependent clonal expansion of initiated B cell populations. In this paper, we demonstrate that oropharyngeal cancer cell lines also express the components of the COX pathway previously reported in plasmacytomagenesis. Further, growth dependence on IL-6 is evaluated to determine whether the progression of OPC could proceed by the mechanisms of inflammatory cross stimulation described by Potter (27) . Based on these results, we have initiated a Phase IIB randomized, placebo-controlled chemoprevention trial. NIH Clinical Center 98-C-0118 evaluates the ability of a general COX inhibitor, ketorolac rinse, to arrest the progression of oropharyngeal leukoplakia.
MATERIALS AND METHODS

Cell lines
Human squamous cell carcinoma cell lines (UMSSC9, 11B, and 38) were derived from patients with advanced head and neck cancer after informed consent under an IRB approved protocol at the University of Michigan and were a generous gift of Dr. Thomas Carey (28) . Squamous carcinoma NA and CA99 -2 cells were derived from oral cavity cancers and were a generous gift of Dr. Toshio Kuroki. The origin and characterization of metastatic cell line PAM LY-2 have been described previously (29 -31) . These lines were cultured at 37°C, 5% CO 2 as adherent monolayer cultures in EMEM (minimum essential medium with Earle's salts) (Life Technologies, Inc./BRL, Gaithersburg, Md.) with 10% heat-inactivated fetal calf serum (Life Technologies, Inc./BRL) containing 2 mM L-glutamine and penicillin (50 g/ml)/ streptomycin (50 g/ml). All cell lines were found to be free of mycoplasma. Log-phase cells were routinely subcultured weekly after trypsinization.
Chemicals
Ketorolac, prostaglandin E 2 Enzyme Immunoassay Kit (PGE 2 -EIA), anti-COX-1 antibody, and anti-COX-2 antibody were both purchased from Cayman Chemical Co. (Ann Arbor, Mich.). MK866 was purchased from Biomol, Inc. (Plymouth Meeting, Pa.). Anti-IL-6 receptor was purchased from Biosource International (Camarillo, Calif.). Standard ELISA assay kits for IL-1␣, IL-6, IL-8, and granulocyte-macrophage colony-stimulating factor (GM-CSF) were purchased from R&D Systems (Minneapolis, Minn.).
mRNA expression
The squamous cell carcinoma cell lines were evaluated for a range of targets involved in AA metabolism including 5-lipoxygenase (LOX), 12-LOX, 15-LOX, FLAP, COX-1, and COX-2 using the reverse transcriptase polymerase chain reaction (RT-PCR) as described previously (32) . Amplification products for 5-LOX, FLAP, 12-LOX, 15-LOX, COX-1, and COX-2 were determined by ethidium bromide staining and Southern blot analysis.
Growth studies
We used a modification of the CellTiter 96 (Promega, Madison, Wis.) semiautomated MTT colorimetric assay, which were performed as previously published (33) . Cells were fed with media containing serum 48 h prior to adding inhibitors, cytokines, or antibodies. After trypsin treatment and washing, cells were maintained in serum-free, keratinocyte-SFM media (Life Technologies, Inc., Grand Island, N.Y.). Seeding densities were 1-2 ϫ 10 4 cells/well; cells were grown for 3 or 4 days during the assays.
PGE 2 analysis
PGE 2 samples were prepared and analyzed by the prostaglandin E 2 Enzyme Immunoassay Kit according to the manufacturer's manual. The cells were incubated for 24 h in defined media (keratinocyte-SFM). Data were analyzed using IBM Software for EIA Data Analysis purchased from Cayman Chemical Co.
Cytokine quantitation
Twelve milliliters of fresh medium were added to tumor cell lines when 50 -70% confluent in 75 cm 2 flasks. After 24 h specimens were collected, aliquoted, and frozen at Ϫ80°C until assayed. Cells were trypsinized and counted, and all results were standardized for amount of cytokine secreted as pg/10 6 cells. Standard ELISA assay kits for IL-1␣, IL-6, IL-8, and GM-CSF were used according to the instructions of the manufacturer (R&D Systems). Standard curves were generated with recombinant cytokine standards provided with each kit and concentrations were determined using least square analysis to a zero order function. Complete medium was used as a blank. Cytokines were quantitated with an EIA plate reader at 450 nm (Biotek 311, Biotek Systems, Winooski, Vt.). All samples were assayed in duplicate.
Western blot analysis
Cells were grown 24 h in EMEM with containing 0.5% serum for 2 days. Cells were then incubated in serum-free media for 2 h, followed by a 20 min incubation in the presence or absence of 10 mg/ml of IL-6. Extracts corresponding to 2 ϫ 10 6 cells were fractionated on 7.5% sodium dodecyl sulfatepolyacrylamide gels, transferred to nitrocellulose membranes, and incubated with specific STAT3 antiserum, phospho-specific (tyr-705) anti-STAT3 (New England Biolabs, Beverly, Mass.). Detection was by enhanced chemiluminescence (Amersham, Arlington Heights, Ill.).
Immunohistochemistry
Cells prepared by cytospin were fixed using 4% formalin and incubated with anti-COX-1, anti-COX-2, or anti-IL-6 receptor primary antibodies (2.5 g/ml) diluted in phosphate-buffered saline containing 1 mg/ml bovine serum albumin for 2 h, rinsed with the same solution for 30 min, and incubated with biotinylated goat anti-mouse immunoglobulin G (1/200 dilution, Vectastain ABC Elite kit, Vector Laboratory, Burlingame, Calif.) for 60 min. The samples were then exposed to avidin-biotin complex (ABC Elite kit, Vector Laboratory) and reacted with diaminobenzidine according to the manufacturer's recommendations and counterstained with hematoxylin.
In vivo treatment of COX inhibitors
All experiments with mice were approved by NINDS Animal Care and Use Committee under protocol 809 -97. PAM LY-2 cell lines were harvested with trypsin/EDTA, washed three times with EMEM, and resuspended at a concentration of 5 ϫ 10 6 cells/200 l EMEM. Male BALB/c mice, 6 -8 wk of age, were inoculated subcutaneously with 200 l of cell suspension in the right flank. Three days after injection of tumor cells, the experimental groups of animals were given ketorolac 0.6 mg/kg body weight in drinking water each day for 5 wk. The control group received water without drugs. Tumor volumes were determined twice a week. Tumor size was calculated using the formula: tumor size ϭ tumor width ϫ tumor length. After the tumor area reached ϳ2 cm 2 , the mice were killed by CO 2 inhalation. The lungs were removed and stained in Bouin's solution for metastases; lung surface metastatic colonies were counted after 5 days.
Statistics
Significance of difference between samples was determined using Student's paired t test. P Ͻ 0.05 was regarded as significant.
RESULTS
Messenger RNA expression of AA metabolizing enzyme in human OPC cells
To confirm that OPC express COX, the target enzyme for ketorolac, we analyzed the mRNA expression of COX by RT-PCR. All OPC lines (nϭ5) tested expressed COX ( Table 1 ). Our previous report shows that ϳ60% of a range of epithelial cancer cell lines express COX-2 whereas all epithelial cell lines tested produce COX-1 (32) . Immunohistochemical analysis demonstrated that both enzymes are produced in the OPC cell lines (Fig. 1A, B) . The finding that COX-2 is consistently expressed in OPC cell lines agree with a previous immunohistochemical study demonstrating the presence of COX-2 in OPC tumor specimens from patients (11) . For comparison, we evaluated the frequency of mRNA from the expression of several AA metabolizing enzymes and related protein 5-lipoxygenase activating protein (FLAP) in OPC ( Table 1) .
Effect of ketorolac on PGE 2 production in OPC cells
PGE 2 is abundantly produced in vitro and in vivo by OPC (34, 35) . When cells are stimulated or free AA is added exogenously, PGE 2 is synthesized and released into the extracellular space. To evaluate the effect of ketorolac on constitutive PGE 2 production, PGE 2 enzyme immunoassays were performed on unstimulated OPC lines treated with ketorolac. Twenty-four hours after ketorolac treatment, the production of PGE 2 in UMSCC9 and UMSCC11B cell lines was greatly reduced, with an IC 50 value of 0.8 and 5 M, respectively ( Fig. 2A) .
Effect of ketorolac on cell growth of OPC cells
Cellular proliferation was next assessed after cell line treatment with ketorolac for 3 or 4 days at concentrations ranging from 10 nM to 100 M. No growth inhibition was observed in any of the five cell lines for this range of concentrations. Comparable results were also seen with indomethacin (data not shown). Serum-free medium was used for these experiments so that serum binding to the inhibitor could be excluded as a cause for the lack of inhibitory effect. Conversely, other experiments with the selective LOX inhibitor MK866 demonstrated marked growth inhibition, suggesting that the other inhibitors of eicosanoid metabolism inhibition may have antiproliferative effects independent of cross talk with the COX pathways (Fig. 2B) . 
Effect of ketorolac on production of cytokines in OPC cells
In human and murine squamous tumor systems, proinflammatory cytokines including IL-1␣, IL-6, IL-8, and GM-CSF are frequently produced and are associated with tumor growth and metastatic progression in vivo (36) . To study the effect of ketorolac on the elaboration of proinflammatory cytokines, cells were cultured with ketorolac under serum-free and serum-containing conditions and analyzed for the effect of ketorolac on cytokine production. Cytokines were quantitated from standard curves obtained with recombinant cytokines and reported as normalized value in pg/10 6 cells/24 h. Ketorolac at 10 and 50 M inhibited IL-8 production by 50% in UMSCC-9 and 25% in the UMSCC-11B cell line.
There was a 30% decrease in IL-6 production with UMSCC11B. However, ketorolac at 10 and 50 M did not significantly affect the production of IL-1␣, and GM-CSF in OPC (Fig. 3A-H) . Negligible effects on cytokine production were observed in 10% serum-containing media, which are consistent with the previous observation in vitro (2, 32) .
Effect of exogenous cytokines on cell growth of OPC cells
It has been hypothesized that proinflammatory cytokines (including IL-6 and IL-8) from tumor cells or their inflammatory infiltrates confer a growth advantage to tumors (30, 36) . To test this hypothesis, cell proliferation experiments were performed with IL-6 or IL-8 added exogenously to the OPC cell lines. When IL-6 (1 ng/ml) was added to serum-free medium, proliferation of three of the oropharyngeal cancer cells increased by 30% to 50% (Fig. 4A-C) .
Exogenously added IL-8 (1 g/ml) increased the growth of UMSCC9 cells by 30% (Fig. 4D ), but did not increase the growth of UMSCC11B (Fig. 4E) or UMSCC38 (Fig. 4F) . To test the specificity of IL-6 stimulation, we added IL-6 receptor antagonist (IL-6 RA) and IL-6 neutralizing antibody (anti-IL-6 Ab) to the culture medium to neutralize endogenous extracellular IL-6-induced proliferation. Neutralizing IL-6 RA at 10 g/ml blocked the activity of IL-6 on UMSCC38 cells (Fig. 5A) , which suggests an IL-6 receptor-specific proliferative effect. Antibody to IL-6 also blocked the activity of IL-6 on UMSCC38 in a dose-dependent manner (Fig. 5B) . These results are consistent with IL-6 stimulating OPC growth in a paracrine fashion; as suggested in Fig. 4 , these cell lines also produce variable amounts of IL-6 in defined media without additional IL-6. The addition of neutralizing antibody to IL-6 or IL-6 receptor had no significant effect on the growth of UMSCC9, which produces small amounts of IL-6 (Fig. 5C ). In contrast, UMSCC11B, which produces large amounts of IL-6, displayed marked growth inhibition when exposed to neutralizing antibody to IL-6 or IL-6 receptor (Fig. 5D ). These results suggest both autocrine and paracrine roles for IL-6 on OPC cell lines.
IL-6 induces STAT signaling in OPC cells
IL-6 receptor is present in the membrane as well as the cytoplasm. This receptor is thought to signal through the phosphorylation of STAT3. To further evaluate the specific nature of this stimulation, we monitored STAT3 phosphorylation in IL-6 receptorpositive UMSCC9 cells (Fig. 1D ) after IL-6 exposure. After 20 min exposure to IL-6, levels of phosphorylated-STAT3 were greatly increased compared to unexposed cells (Fig. 1E) , suggesting that functional IL-6 receptors were present in the OPC cell lines.
COX inhibitors reduce tumor growth in vivo
Although ketorolac did not reduce in vitro OPC growth, we determined whether it could exert an anti-proliferative effect by disrupting paracrine effects of IL-6 producing cell populations in vivo. To evaluate this possibility, we used the aggressive in vivo, syngeneic murine squamous cell cancer model LY-2. This model was selected because it has been extensively characterized with regard to its cytokine production of IL-6 (29, 30) . Treatment of tumorbearing mice daily with ketorolac for 3 wk produced a statistically significant reduction in tumor size (PϽ0.01) (Fig. 6) . Also metastatic dissemination of LY-2 was detected in three of five (60%) control mice compared to only two of eight (25%) ketorolac treated mice. Comparable results were also seen with indomethacin (data not shown).
Effect of HL-60 conditioned medium (CM) on growth of OPC cells
To test the hypothesis that inflammatory cells (including tumor-associated monocytes) may elaborate growth-conferring substances to the tumor milieu, we used CM from promyelocytic HL-60 cells. Treatment of HL-60 cells with phorbol esters (TPA) induces macrophage-like differentiation (37) . Differentiated HL-60 cells have enhanced ability to produce varieties of growth factors and cytokines. The amount of IL-6 produced by HL-60 cells increased from 100 ng/ml to 160 ng/ml after TPA stimulation.
In proliferation experiments, we observed that CM from TPA-stimulated HL-60 cells increased the proliferation of UMSCC9 cells by 100% over CM from non-TPA-exposed HL-60 cells (Fig. 7) . Neutralizing antibody to IL-6 receptor shows that CM-induced growth stimulation was blocked in a dose-dependent manner (Fig. 8) . These data suggest that differentiated HL-60 CM mediates growth stimulation via IL-6 receptor activation.
DISCUSSION
Although favorable clinical responses of OPCs to pan-COX inhibitors were previously reported, these drugs are not used in the conventional treatment of OPC (38) . In the current report, both COX-1 and COX-2 isoforms were found to be expressed by all five OPC lines compared to a frequency of 60% for COX-2 expression that we reported for other types of epithelial cancer cell lines (32) . Dannenberg and co-workers (11) recently reported abundant expression of COX-2 mRNA and protein in tumor specimens from patients with head and neck cancer contrasted with low expression in adjacent normal tissue. Taken together, these data are consistent with COX activity having an important role in oropharyngeal carcinogenesis.
Prostaglandins are mediators of a wide variety of pathophysiological processes; increased levels of prostaglandins have been reported with human OPC as well as with other epithelial cancer cells (34, 35) . OPC cells can express a range of proinflammatory cytokines such as IL-1␣, IL-6, IL-8, and GM-CSF at variable concentrations. These cell products can partake in a complex set of autocrine, paracrine, and/or endocrine interactions (36) . Our results with COX inhibition by ketorolac were similar to a parallel experiment with indomethacin in regard to the production of PGE 2 , cytokines as well as in vitro and in vivo growth (data not shown). Ketorolac was specifically formulated for local delivery and mucosal penetration in the oral cavity to control the infectious inflammatory disease, periodontitis (39) . In randomized, double-blind, placebo-controlled clinical trials, ketorolac administered twice daily has been shown to consistently arrest the progression of periodontal disease and significantly decrease the oral mucosal levels of PGE 2 (40) . Using OPC cell lines, ELISA analysis showed that ketorolac significantly reduced the in vitro production of IL-6 and IL-8, but did not directly affect the production of IL-1␣ and GM-CSF. Despite this marked effect on reduction of specific cytokine levels, the pan-COX inhibitor ketorolac did not inhibit in vitro proliferation of any of the oropharyngeal cancer cell lines at 72-96 h. This is the same situation described by Potter (27) for the in vitro response of B cell populations to another pan-COX inhibitor, indomethacin. In contrast to the in vitro situation, ketorolac was effective in significantly reducing the in vivo tumor growth of OPC. This finding is also consistent with Potter's finding of indomethacin causing in vivo inhibition of plasmacytomagenesis in BALB/c mice (27) . This result with in vivo COX inhibition was the basis for Potter's mechanistic proposal, which suggests a pivotal role for chronic prostaglandin-dependent inflammation in promoting plasmacytomagenesis. The presence of cytokine-producing inflammatory cells for the in vivo experiments but not for the in vitro assay may be the basis for the differential sensitivity to the COX inhibitors. Stimulated macrophage populations produce a variety of inflammatory mediators that could potentially exert growth-promoting effects on clonal populations of epithelial cells. Our working model involving interaction of COX and inflammatory mediator is presented in Fig. 9 . Other exogenously added proinflammatory cytokines such as IL-8 can also increase the growth of OPC, so we suspect that these cross feeding effects are a general phenomenon.
The presence of IL-6-responsive signaling circuits in OPC is a recent observation, but the ability of epithelial cells to respond to immune cell products is well supported (41) . Proinflammatory and proangiogenic cytokines produced by squamous cancer cells have been suggested to play an important role in promotion of tumor progression, highlighting the importance of the interaction between malignant cells and surrounding inflammatory cells (27, 29, 30, 36, 42) . The cross feeding of the OPC cells with the conditioned media from TPA-exposed HL-60 cells was an attempt to model the type of community interactions mediated by COX activation that are relevant to in vivo carcinogenesis. Such proposed paracrine interactions are similar to the type of community interactions found in prokaryotic systems such as bacterial biofilm (43) . Short-term cultures of activated macrophages could have been used as an alternative source of IL-6, but it is difficult to standardize reproducible experimental conditions. Whereas there are good sources of mouse macrophage lines, the availability of human macrophage lines is much more limited. We used UMSCC9 for the cross feeding experiments because the amount of autocrine IL-6 produced by this cell line was minimal and not required for growth as was the case with UMSCC11B as shown in Fig. 5C , D. The in vitro production of proinflammatory cytokines is heterogeneous both quantitatively and qualitatively (30, 36) . We speculate that this repertoire of cytokine production is more frequent in cell lines established from advanced cancers. Early clonal population of initiated cells in the oral cavity may be more consistently dependent on the cytokines produced locally by the non-cancer cell population. This possibility is supported by the epidemiological data, which sug- gest chronic COX inhibition results in reduced risk for colon cancer development (44) .
Several alternatives have been proposed for the mechanism by which COX has an effect on epithelial cell growth (26, 45, 46) . Kinzler and co-workers have suggested a role for the buildup of ceramide in response to COX inhibition as triggering apoptosis and accounting for the anti-proliferative effect of these compounds (47) . The induction of apoptosis by ceramide is well established, but the relative contribution of this mechanism to the inhibition of carcinogenesis in this context is unclear (48) . Although the mechanisms are not mutually exclusive, further analysis of the relative importance of these two mechanisms is warranted.
We used ketorolac as a pan-COX inhibitor in this study since it was developed as a rinse for use in the oral cavity to block prostanoid activity without incurring gastrointestinal adverse effect (39) . Though this favorable therapeutic index makes direct delivery of ketorolac attractive as a chemoprevention candidate, there is another benefit of being able to use a pan-COX inhibitor to arrest the progression of OPC. Emerging data suggest that COX-1 activity overlap with COX-2 in the carcinogenic process (24 -26, 39, 49) , implying that pan-COX inhibition may be required for effective long-term treatment and/or prevention of OPC.
In conclusion, our initial experiments suggest a pivotal role for IL-6 as an autocrine or paracrine product in oropharyngeal cancer cell regulation. This type of cross feeding mechanism could involve other cytokines as well. Indirect regulation of inflammatory cytokines by COX in non-neoplastic cells may drive cancer cell growth in a paracrine fashion, providing a direct link between the biology of cancer and inflammation. We also recognize that sources of cytokine production may not originate solely from inflammatory cells, but from other local cells such as the epithelium and stromal cells (50) or the tumor itself, as shown in this report. There is a growing awareness of the complex contribution of the microenvironment to the induction of a cancer. Examples of this include the relationship of epithelial cell interaction with the stroma (51) . A more complete understanding of such issues is critical, especially with regard to developing more relevant models for drug discovery. The contribution of proinflammatory cytokines to other chronic diseases is emerging (19) . Our report suggests that the cytokine-rich oral environment of an individual with periodontal disease could contribute to accelerating carcinogenesis. Recent data also suggest a contributory role of gram-negative periodontal pathogens being associated with increased levels of circulating cytokines and elevated risk of cardiovascular disease (52, 53) . Taken together, these results may force a reconsideration of the significance of an unbridled chronic inflammatory condition such as periodontal disease relative to its contribution to other more ominous health conditions. Local inhibition of COX may be of particular strategic importance in this context.
